ResMed Inc. stock (US7611521078): Recent price dynamics signal trading opportunities

ResMed Inc. shares show buy signals from moving averages and a broken short-term uptrend, with support levels at $40.36 and resistance near $43.42, per recent technical analysis.

ResMed Inc., a leader in respiratory care devices, recently broke its short-term rising trend, indicating potential for stronger upward momentum. Support levels are noted at $41.15, $40.36, and $39.27, while resistance may appear at $43.42, according to StockInvest.us as of May 2026. The stock holds positive signals from short- and long-term moving averages.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: United States
• Core markets: US, international
• Key revenue drivers: Sleep apnea devices, respiratory software
• Home exchange/listing venue: NYSE (RMD)
• Trading currency: USD

ResMed Inc.: core business model

ResMed Inc. develops, manufactures, and distributes medical devices and cloud-based software for diagnosing and treating respiratory disorders, including sleep apnea. The company focuses on continuous positive airway pressure (CPAP) masks, ventilators, and digital health solutions. Products are marketed globally, with a strong presence in the US market, where demand for sleep disorder treatments drives growth, as detailed on Simply Wall St overview.

ResMed's SaaS offerings, like myAir, provide patient engagement tools integrated with devices. This model supports recurring revenue through software subscriptions alongside hardware sales. The firm's innovation in connected devices positions it well in the growing telehealth sector relevant to US investors.

Main revenue and product drivers for ResMed Inc.

Sleep and respiratory care devices account for the majority of revenue, with CPAP machines and masks as key products. In recent periods, digital health revenue has expanded, per company descriptions. The US represents a core market, benefiting from high obesity rates linked to sleep apnea prevalence.

Product launches and software updates drive growth. ResMed reported a market cap around $30 billion with a P/E of 19.92 as of May 2026, according to INDmoney data as of 05/11/2026. This underscores its scale in the medtech space.

Industry trends and competitive position

The respiratory care market benefits from rising awareness of sleep disorders and aging populations. ResMed competes with players like Philips Respironics but leads in digital integration. US market exposure makes it sensitive to healthcare reimbursement policies and consumer spending.

Why ResMed Inc. matters for US investors

Listed on NYSE, ResMed offers US investors direct access to a medtech leader with substantial domestic revenue. Its focus on chronic disease management aligns with US healthcare trends, including Medicare coverage for CPAP therapy.

Conclusion

ResMed Inc. continues to show technical buy signals amid its strong position in respiratory care. Recent price action highlights support and resistance levels worth monitoring. Investors track medtech trends and company updates for context on NYSE-listed shares.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.